Metformin has been a cornerstone in managing type 2 diabetes primarily known for its effects on the liver and gut. For over 60 years, this medication has helped millions control their blood sugar levels, but recent developments suggest that its influence extends into the brain.
New research indicates that metformin operates by shutting down a protein called Rap1 in the ventromedial hypothalamus, a crucial area of the brain involved in energy balance and metabolism. This discovery has prompted experts to rethink the drug’s role, as highlighted by researcher Makoto Fukuda, who stated, “This discovery changes how we think about metformin.”
Fukuda elaborated that metformin not only affects the liver and intestines but also acts within the brain, suggesting a more complex mechanism of action than previously understood. “It’s not just working in the liver or the gut, it’s also acting in the brain,” he noted.
Interestingly, the study found that while the liver and intestines require high concentrations of metformin to respond, the brain reacts to much lower levels of the drug. This could explain why metformin is associated with various health benefits beyond diabetes management, including slowing brain aging.
In fact, metformin is considered a gerotherapeutic, capable of slowing down various aging processes in the body. A 2025 study revealed that metformin users had a 30% lower risk of dying before age 90 compared to those using sulfonylurea, further emphasizing its potential longevity benefits.
Moreover, metformin has been shown to reduce wear and tear in the brain and may even lower the risk of long COVID, adding to its growing list of health advantages. However, it is important to note that 75% of those taking metformin experience gastrointestinal problems, which can limit its use for some patients.
As the research unfolds, observers are keenly watching how these findings will influence future studies and clinical practices. The implications of metformin’s brain effects could lead to new therapeutic strategies for not only diabetes but also age-related cognitive decline.
With the scientific community now aware of metformin’s broader implications, further investigations are expected to explore its potential in neuroprotection and cognitive health. Details remain unconfirmed, but the excitement surrounding these findings is palpable.
